Bringing the best drugs
to the right patients

 
  • Mon
    April
    14
    2014

    Novadiscovery to represent the SysCLAD consortium at the 20th-anniversary edition of the prestigious International Congress on Lung Transplantation, in Paris.

    Novadiscovery is proud to announce, on behalf of the SysCLAD Consortium, its participation to the session on "Chronic Lung Allograft Dysfunction (CLAD)", a serious condition that currently impedes lung transplantation to have a bigger impact in the treatment of end-stage lung diseases. This prestigious scientific meeting constitutes the perfect opportunity to showcase Novadiscovery's unique technology and ability to unlock new avenues for the discovery of biomarkers in the context of a multi-factorial and highly heterogenous chronic disease. The SysCLAD Consortium is a FP7-funded initiative that seeks to explore, through a multidisciplinary approach, novel strategies towards the early diagnosis and treatment of CLAD.
  • Tue
    January
    28
    2014

    Benefit Risk Impact consortium

    Novadiscovery is proud to announce the official launch of the Benefit Risk Impact consortium destined to help pharmaceutical companies navigate the pre- and post-approval cycles. The launch conference was a success, with notable interest for our unique offering both from pharmaceutical company executives as well as regulatory agencies.
  • Tue
    December
    10
    2013

    Sanofi Pharmacometrics

    Novadiscovery's CEO is presenting the company during Sanofi's Pharmacometry & bioinformatics conference in Paris.
  • Fri
    November
    8
    2013

    Big Data & Analytics for Pharma, Philadelphia

    Novadiscovery's CEO will give a talk on the hot topic of big data applied to pharmaceutical R&D: "Beyond big data: from systems biology to real-world patient outcomes". With the growing interest in computer-based applications to new drug R&D, a host of innovative technologies have emerged in the recent years, from bioinformatics to systems biology. However promising, these approaches share a number of limitations, chief among them their focus on omics data and the implicit assumption that living systems are built from a limited number of standard parts and that interactions are encoded in genes. Against this backdrop, systems medicine purports to develop a holistic representation of a disease to predict the end results of a given alteration on real patients, thus bridging systems biology and real-world outcomes.
  • Wed
    October
    9
    2013

    EUCROF Conference 2013, Brussels

    Novadiscovery's CEO will give a talk as part of the session 7: New Approaches in Clinical Trials on the following topic: “Clinical Trial Simulation: a Centerpiece in the Model-based Drug Development‘’.
  • Tue
    June
    25
    2013

    Novadiscovery becomes Associated Partner to the European project CASyM

    The Coordinating Action Systems Medicine (CASyM) is a multidisciplinary European consortium that joins forces to develop an implementation strategy (road map) for Systems Medicine.
  • Wed
    June
    12
    2013

    Novadiscovery receives coverage from Wired

    Novadiscovery draws attention from Wired, the pioneering publication which epitomizes geek culture and the Silicon Valley's innovative drive.
  • Mon
    June
    10
    2013

    Nature Biotechnology: combining breakthrough predictive R&D and financial engineering

    Our CEO's letter to the editor emphasizes the need to adopt predictive mathematical modeling to make the securitization of R&D assets an operational reality.
  • Wed
    May
    1
    2013

    A publication by P A Milligan et al: Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development.

    A team of scientists from Pfizer gives an account of the benefits of quantitative modeling applied to clinical development programs in the company's pipeline. US$ 100 million of annual savings through the reduction of trials' size and duration. In Clinical Pharmacology & Therapeutics (2013); 93 6, 502–514.
  • Mon
    March
    11
    2013

    CanceRX: New Approaches to Commercializing Biomedical Research at MIT in Cambridge (16-18 June 2013)

    The conference will focus exclusively on new approaches to commercializing biomedical research in oncology through financial engineering. Bringing together representatives from key stakeholder communities—including academia and medical research centers, community hospitals, the biopharma industry, health plans, government agencies, patient advocacy groups, investment banks, hedge funds, credit rating agencies, biotech venture capitalists, and institutional and retail investors.
    • Location : Cambridge, United States
  • Sat
    March
    2
    2013

    BioVision CASyM Round Tables

    Novadiscovery CEO François-Henri Boissel will chair the RT4 focused on New Business Models for Systems Medicine (9:00 to 11:30).
  • Thu
    February
    28
    2013

    EUnetHTA releases guideline on relative effectiveness

    Novadiscovery, a leading company in R&D risk management and health care predictive modeling, is pleased to announce its Effect Model approach gains recognition in the context of relative effectiveness analysis of pharmaceuticals. A critical step towards the widespread adoption of our methodology to base market access, pricing and reimbursement decisions.
  • Fri
    February
    15
    2013

    BioVision Catalyzer

    Novadiscovery CEO François-Henri Boissel will present the SysCLAD project in Focus 5: personalized medicine (8:30 to 11:15). Make sure you vote to support our project, with the following link:
    • Location : Lyon, France
  • Fri
    November
    23
    2012

    Novadiscovery participates in a conference on innovation in mathematical modelling at INRIA

    Jean-Pierre BOISSEL, Professor Emeritus and co-founder of Novadiscovery, takes part in the scientific debate "mathematical modelling in healthcare : from bioinformatics to numerical cells".
  • Wed
    October
    3
    2012

    BIO-Europe 2012 • 13 November 2012, 3.40 pm • Hamburg, Germany

    On Tuesday 13 November 2012, at 3.40 pm, Novadiscovery will make a 7 minutes company presentation during the convention covering our background, key products and technologies, existing and future alliances.
  • Wed
    September
    26
    2012

    Novadiscovery announces a grant under the 7th Framework Programme of the European Commission

    Novadiscovery, a leading company in health care predictive modeling and knowledge management, is proud to announce it is teaming up with the European Institute for Systems Biology and Medicine (EISBM) and leading lung transplantation clinicians on an FP7 collaborative project which ambitions to bring personalized medicine solutions at the bedside to improve survival for post-lung transplant patients.
  • Thu
    July
    12
    2012

    BioHealth Computing Program career fair

    Novadiscovery participates to the BioHealth Computing Program career fair in Archamps, France
  • Mon
    July
    2
    2012

    Presentation to EMBL-EBI & Wellcome Trust Resources

    Novadiscovery presents a poster on infectious disease modeling during the joint EMBL-EBI & Wellcome Trust Resources for Computational Drug Discovery Course in Cambridge, UK
  • Tue
    June
    19
    2012

    Lung Transplatation Scientific Day

    Novadiscovery presents the SysCLAD project at the Cohort in Lung Transplatation Scientific Day organized by the Institute for Therapeutic Research of the University of Nantes, France
  • Mon
    June
    18
    2012

    Bio Boston 2012

    Meet Novadiscovery at the 2012 Bio International Convention in Boston, MA (booth 1043 in the French pavilion).
  • Wed
    June
    13
    2012

    Novadiscovery at the EISBM workshops on knowledge management

    Novadiscovery presents the company at the European Institute for Systems Biology & Medicine workshops on knowledge management in Lyon, France
  • Sat
    May
    12
    2012

    SysCLAD project final negotiation stage

    Novadiscovery enters the final negotiation stage for the FP7 SysCLAD project
  • Tue
    April
    24
    2012

    Epitech's career fair

    Novadiscovery participates to Epitech's career fair in Lyon, France
  • Fri
    April
    6
    2012

    7th Congress of Physiology, Pharmacology and Therapeutics

    Novadiscovery presents results on HPV modeling at the 7th Congress of Physiology, Pharmacology and Therapeutics in Dijon, France
  • Fri
    March
    16
    2012

    Novadiscovery at the Sepsis collaborative days

    Novadiscovery presents intermediary results of its sepsis R&D program at the Sepsis collaborative days in Lyon, France
  • Thu
    February
    2
    2012

    Collaboration with Alosta

    Novadiscovery and Alosta enter into a collaboration agreement whereby Alosta will support Novadiscovery's business development efforts with a focus on promoting the science and technology and sourcing drug assets to feed the company's partnered Securitized financing programs
  •  

Benefit Risk Impact
The BRI Global Solutions consortium

In the face of intensifying pressure by regulators and payers to demonstrate a drug’s real-life effectiveness, Novadiscovery teams up with Cegedim Strategic Data to help pharmaceutical companies navigate the pre- and post-market approval cycles.

MORE  The BRI Global Solutions consortium

Why

The traditional biopharmaceutical R&D paradigm needs a radical rethink

Because biomedical knowledge is being wasted on an epic scale

The biomedical knowledge capital is doubling every ten years since the fifties. But this continuous inflow of scientific findings fails to be translated into improved therapeutic innovation and patient care capabilities.

We believe mathematical formalism is the only available tool to structure and leverage this ever increasing stock of knowledge.

Because complexity stifles innovation

Beyond the sheer quantity of knowledge readily available in the scientific literature and its heterogeneous nature - drawing on multiple domains of expertise, living organisms are complex systems characterized by retroactions and redundancies. Furthermore, these systems are based on quantitative relationships between their constituent biological entities.

The mathematical representation of living systems can help manage this complexity and open up new avenues for breakthrough treatments.

Because truly innovative treatments are out of reach of traditional R&D approaches

The traditional R&D paradigm is characterized by serendipity, trial-and-error and costly back-dated failures. The only available gold standard to evaluate a compound's efficacy is the Phase III of clinical trials, at the very end of the R&D process.

Predictive analytics can expand the scope of research for breakthrough drugs and turn R&D into a structured process where compound efficacy is measured long before clinical trials. Failures can thus be identified upstream to reduce attrition costs.

Because different patients react differently to the same drug

A drug's efficacy is not a digital outcome: efficacious or inefficacious. It is a quantity, measured in terms of clinical event risk reduction, which varies from one patient to another.

Furthermore, idealized Phase III clinical trials results give limited guidance as to how the compound will fare on real patients in a given population or group (American, female caucasian, etc.).

What is needed is a methodology to predict, for each patient, the quantity of efficacy derived from available treatments for a given condition. This will pave the way for the implementation of personalized medicine in day-to-day practice.

It is also imperative to translate Phase III clinical trials results into real-life outcomes to establish a compound's efficacy relative to competitor products already available on the market.

How

Novadiscovery is leading the shift from a R&D model that relies heavily on serendipity to one driven by knowledge-based mathematical modeling and predictive analytics

By fixing the innovation machine

The entirety of drugs produced since the birth of the pharmaceutical industry in the late 19th century were discovered on the back of c.500 therapeutic targets. But the human body contains tens of thousands of potential drug targets which remain unexplored to this day.

A mathematical model of a disease process enables the structured exploration of a large number of such potential targets and their combinations, which are beyond the reach of current exploratory approaches.

By rationalizing drug development

Mathematical models and predictive analytics can be used as a sandbox to explore multiple assumptions cheaper and faster than with traditional approaches.

In particular, Novadiscovery can help funnel down the most promising scenarios to be explored in-vitro and in-vivo. For e.g., optimal dose-effect relationships can be determined in silico to reduce the number of necessary real life trials.

In silico simulation is not meant to replace traditional in-vitro and in-vivo trials. Rather, it should be used ex ante to optimize these trials and making them cheaper and faster to complete.

By demonstrating a drug's value in real life

The payer-driven market is shifting from buying products to buying outcomes on real patients. Drug pricing and reimbursement decisions are increasingly based on evidence of effectiveness relative to competitor products.

The Effect Model law, discovered by Novadiscovery’s co-founder and Chief Scientific Officer, enables the prediction of real patient outcomes long before clinical trials. The resulting estimation of a drug candidate’s value can be benchmarked against competitors to establish proof of commercial relevance upstream.

By identifying the best treatments for the right patients

The same analytical framework can be applied in daily medical practice. Given a condition, optimal treatment selection should be based on a prediction of the Absolute Benefit (i.e. risk reduction) specific to each patient for each available treatment option in order to determine the best drug for the right patient.

What

Novadiscovery applies its unique technology from the early stages of pharmaceutical research all the way to day-to-day patient care

Analytical solutions to improve R&D outcomes

When applied to a given R&D program, the Effect Model law offers the ability to explore a virtually limitless range of scenarios and measure their consequences in terms of outcomes on real patients.

Our unique suite of analytical solutions enables informed R&D decision-making to optimize resources allocations.

Consulting solutions to demonstrate value in real life

The Benefit Risk Impact (BRI) Global Solutions consortium brings together a unique set of expertise to help pharmaceutical companies navigate the regulatory environment in pre- and post-market approval cycles.

Novadiscovery partners with Cegedim Strategic Data and a number of expert academic research units to offer integrated consulting solutions structured around a unique access to large patient databases, analytics and modeling, epidemiology, regulatory affairs and public health expertises.

Applications to personalize medicine

Our mathematical disease models and virtual populations can be leveraged in daily medical practice. For a given patient and a given condition, each available treatment will be ranked according to its predicted efficacy.

Novadiscovery offers physicians and clinicians access to web applications in order to optimize treatment selection decisions.

Who

Our people assemble a unique set of expertise to bring disruptive solutions to our customers and partners

Careers

Our success ultimately depends on the quality of our human capital. We look for people with a passion for excellence, a belief in the power of the team, integrity and leadership.

Contact

Feedback & enquiries

Optional
Close